Categories: "Cancer Therapeutics"
Reference #: 2015-027
A considerable limitation of current therapies to treat prostate cancer is the development of resistance tofront-line anti-androgens. Prostate tumors that progress following ineffective androgen ablation therapy often develop a more aggressive androgen – independent tumor (castration-resistant prostate cancer (CRPC) Second generation anti-androgens such as enzalutamide (Xtandi®) have shown promise in treating CRPC through the disruption of androgen receptor (AR) signaling, but tumors have shown resistance to these therapies as well.
Georgetown researchers have identified a novel small molecule that suppresses AR signaling to an extentsimilar to enzalutamide and a similar second-generation anti-Androgen ARN-509. This agent is effective at suppressing ARv7 signaling, and demonstrates efficacy in cell lines that demonstrate resistance to enzalutamide and ARN-509. This composition may represent a next-generation of AR targeting therapies to treat CRPC.
Potential treatment for castration-resistant prostate cancer (CRPC)
Stage of Development
In vitro data demonstrating mechanism of action and tumor cell sensitivity
Patent application filed.